The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Bristol-Myers Squibb (Inst)
Auto-reactive antibodies as predictive markers for immune checkpoint–induced pneumonitis.
 
Mehmet Altan
Consulting or Advisory Role - AstraZeneca; BMS; GlaxoSmithKline
Speakers' Bureau - Nektar
Research Funding - Adaptimmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Shattuck Labs (Inst)
Travel, Accommodations, Expenses - Nektar
 
Qi Wang
No Relationships to Disclose
 
Quan-Zhen Li
No Relationships to Disclose
 
Chengsong Zhu
No Relationships to Disclose
 
Hai T. Tran
Research Funding - Bayer (Inst); Bristol Myers Squibb (Inst); Guardant Health (Inst); ZIOPHARM Oncology (Inst)
 
Ajay Sheshadri
No Relationships to Disclose
 
Saumil Gandhi
No Relationships to Disclose
 
Mara Antonoff
No Relationships to Disclose
 
Stephen Swisher
Honoraria - Armada Health Care (I); Merck (I)
Research Funding - CairnSurgical (I); Lilly (I); Lumicell (I); OncoNano Inc (I)
Travel, Accommodations, Expenses - Peter MacCallum Cancer Center
 
Natalie I Vokes
Honoraria - Sanofi
Consulting or Advisory Role - Sanofi/Regeneron
 
Amy R. Spelman
No Relationships to Disclose
 
J. Jack Lee
Honoraria - AstraZeneca; AstraZeneca
 
Jianjun Zhang
Honoraria - CancerNet; Geneplus; Geneplus; Innovent Biologics; innovent biologics; Innovent Biologics; Origimed; Roche; Sino-USA Biomedical Platform; Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; Capital Medical University; Geneplus; Johnson & Johnson/Janssen; Novartis
Research Funding - Merck; Novartis
Travel, Accommodations, Expenses - innovent biologics; Zhejiang Cancer Hospital
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; BrightPath Biotheraputics; Bristol-Myers Squibb; Catalyst Biotech; EMD Serono; Foundation medicine; Genentech/Roche; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Janssen; Kairos Ventures; Leads Biolabs; Lilly; Mirati Therapeutics; Nexus Health Systems; Novartis; Pneuma Respiratory; Roche; Sanofi/Aventis; Spectrum Pharmaceuticals; Takeda
Research Funding - AstraZeneca (Inst); GlaxoSmithKline; Spectrum Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations